Apogem Capital LLC Pro Qr Therapeutics N.V. Transaction History

Apogem Capital LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.74 - $0.89 $628 - $755	-849 Reduced 0.68%	124,424 $93,000
Q2 2022 Aug 15, 2022	BUY	$0.56 - $1.0 $45,568 - $81,373	81,373 Added 185.36%	125,273 $97,000
Q1 2022 May 16, 2022	BUY	$0.9 - $8.39 $15,322 - $142,839	17,025 Added 63.35%	43,900 $40,000
Q4 2021 Feb 14, 2022	BUY	$6.58 - $8.44 $33,196 - $42,579	5,045 Added 23.11%	26,875 $215,000
Q3 2021 Nov 15, 2021	SELL	$5.16 - $8.47 $52,668 - $86,453	-10,207 Reduced 31.86%	21,830 $183,000
Q2 2021 Aug 16, 2021	SELL	$5.75 - $7.59 $15,047 - $19,863	-2,617 Reduced 7.55%	32,037 $216,000
Q1 2021 May 14, 2021	BUY	$4.14 - $9.22 $77,827 - $173,326	18,799 Added 118.57%	34,654 $229,000
Q4 2020 Feb 16, 2021	BUY	$3.58 - $4.85 $56,760 - $76,896	15,855 New	15,855 $67,000

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $151M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Apogem Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Apogem Capital LLC with notifications on news.